Becton, Dickinson and Company (NYSE:BDX) CEO Sells $768,120.00 in Stock

Becton, Dickinson and Company (NYSE:BDX) CEO Thomas Polen, Jr. sold 4,152 shares of the business’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. The trade was a 3.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Becton, Dickinson and Company Stock Performance

BDX stock opened at $183.16 on Monday. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The firm has a market cap of $50.47 billion, a price-to-earnings ratio of 55.17, a PEG ratio of 12.93 and a beta of 0.19. The business’s fifty day simple moving average is $157.84 and its two-hundred day simple moving average is $161.41. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The firm had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the previous year, the business earned $3.68 earnings per share. Becton, Dickinson and Company’s quarterly revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 126.51%.

Wall Street Analyst Weigh In

BDX has been the topic of several research analyst reports. Piper Sandler boosted their target price on Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Royal Bank Of Canada increased their price objective on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a report on Thursday. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Stifel Nicolaus set a $195.00 target price on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Finally, Barclays boosted their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $185.67.

Hedge Funds Weigh In On Becton, Dickinson and Company

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Imprint Wealth LLC acquired a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth about $25,000. SHP Wealth Management purchased a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth $26,000. Meeder Asset Management Inc. raised its position in Becton, Dickinson and Company by 152.2% in the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 102 shares in the last quarter. Main Street Group LTD acquired a new stake in Becton, Dickinson and Company in the first quarter valued at approximately $29,000. Finally, Bell Investment Advisors Inc acquired a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at $29,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.